Illumina, Inc. (NASDAQ:ILMN) Position Reduced by GSA Capital Partners LLP

GSA Capital Partners LLP reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 53.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,690 shares of the life sciences company’s stock after selling 3,063 shares during the quarter. GSA Capital Partners LLP’s holdings in Illumina were worth $351,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Cetera Advisors LLC acquired a new stake in Illumina in the 1st quarter valued at about $610,000. Weybosset Research & Management LLC increased its holdings in shares of Illumina by 92.0% in the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock valued at $2,354,000 after buying an additional 8,650 shares in the last quarter. B. Riley Wealth Advisors Inc. lifted its position in shares of Illumina by 176.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock valued at $749,000 after acquiring an additional 4,579 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Illumina by 3.6% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company’s stock worth $41,748,000 after acquiring an additional 13,725 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Illumina by 65.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 32,806 shares of the life sciences company’s stock worth $4,278,000 after acquiring an additional 12,986 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Up 2.3 %

Illumina stock opened at $140.14 on Friday. The company has a market capitalization of $22.23 billion, a P/E ratio of -14.07 and a beta of 1.13. Illumina, Inc. has a 1-year low of $93.51 and a 1-year high of $156.66. The firm’s fifty day simple moving average is $140.61 and its 200-day simple moving average is $124.76. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business’s revenue was down 3.5% compared to the same quarter last year. During the same period last year, the company earned $0.33 earnings per share. Sell-side analysts forecast that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Barclays increased their price target on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Canaccord Genuity Group lifted their target price on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a research report on Tuesday, November 5th. Daiwa America upgraded shares of Illumina to a “strong-buy” rating in a research report on Friday, August 16th. TD Cowen lifted their price objective on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, StockNews.com started coverage on Illumina in a report on Thursday, August 29th. They issued a “buy” rating for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $164.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.